Does Renin-Angiotensin System Blockade Protect Lupus Nephritis Patients From Atherosclerotic Cardiovascular Events? A Case-Control Study. - Wikidata - wikimedia - TriplyDB

Does Renin-Angiotensin System Blockade Protect Lupus Nephritis Patients From Atherosclerotic Cardiovascular Events? A Case-Control Study.

Does Renin-Angiotensin System Blockade Protect Lupus Nephritis Patients From Atherosclerotic Cardiovascular Events? A Case-Control Study.

http://www.wikidata.org/entity/Q38909471

about

Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis.

P2860

Q50052184-E42DE097-8924-49D5-9854-D347FEE52023

P2860

Does Renin-Angiotensin System Blockade Protect Lupus Nephritis Patients From Atherosclerotic Cardiovascular Events? A Case-Control Study.

http://www.wikidata.org/entity/Q38909471

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Does Renin-Angiotensin System ...... Events? A Case-Control Study.

@en

type

label

Does Renin-Angiotensin System ...... Events? A Case-Control Study.

@en

prefLabel

Does Renin-Angiotensin System ...... Events? A Case-Control Study.

@en

P1433

Q38909471-B60516E3-548A-47D2-91F2-37E3FF094369

P1476

Q38909471-9E53C64B-B73E-426B-9053-FFDA21AB0B24

P2093

Q38909471-0A57EB8E-1CC0-4F94-B7DA-FC1173A57BD1

Q38909471-56CD166D-4A98-4A33-9A63-81BCF4F73440

Q38909471-CC1E7938-7934-4F9C-91B6-F6078457494C

P2860

Q38909471-04F9B817-DD34-481A-BB29-124FD4E716E1

Q38909471-09968522-23DD-484A-8231-C10952B03149

Q38909471-0E28F742-6869-4624-82B9-C5913AB85D9A

Q38909471-1981B1F9-57B2-4410-9F93-55C7803804E8

Q38909471-236599FE-F551-49E1-A49C-EEBC74F21543

Q38909471-23A07161-89BD-41C9-8D7B-F56EF703C5CC

Q38909471-2F5B0AC7-1830-4B26-ACE6-2F3A495FB4CB

Q38909471-33C1E620-E344-46C1-B300-F495E738D75D

Q38909471-41F934C7-C4BE-483D-BBF3-1BD2E4B772E4

Q38909471-4D95D0F5-A240-44CC-AE14-C89720AE6676

P304

Q38909471-5429A004-17D3-4BD6-BEF6-1975B063DAC7

P31

Q38909471-546173B3-D505-4597-A458-F77E7B9345CB

P356

Q38909471-47CAA5EB-D35C-417F-ABD7-A0FD0EE2556A

P433

Q38909471-014015D6-CB56-4AED-91C5-C8D47F89616F

P478

Q38909471-FB946709-E905-4512-BF74-C4EECDBC399F

P50

Q38909471-26352E2B-4ED9-4F33-B539-EDDF6642176D

P577

Q38909471-8C0E1562-107C-4DC8-BA7F-A713E6E9EA5C

P698

Q38909471-983C6B09-4213-4722-90E7-1CCCE8170380

P921

Q38909471-C2057198-A51B-4DE3-A165-DD35A37018C0

P356

P1433

Arthritis Care and Research

P1476

Does Renin-Angiotensin System ...... Events? A Case-Control Study.

@en

P2093

Jiandong Su

http://www.w3.org/2001/XMLSchema#string

Konstantinos Tselios

http://www.w3.org/2001/XMLSchema#string

Murray B Urowitz

http://www.w3.org/2001/XMLSchema#string

P2860

Immunity in arterial hypertension: associations or causalities?

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

Use of atorvastatin in systemic lupus erythematosus in children and adolescents

Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus--results from LUMINA (LIX): a multiethnic US cohort

2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study

Premature atherosclerosis is associated with hypovitaminosis D and angiotensin-converting enzyme inhibitor non-use in lupus patients.

Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.

An ACE inhibitor reduces Th2 cytokines and TGF-beta1 and TGF-beta2 isoforms in murine lupus nephritis.

Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus

P304

1497-1504

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ACR.22857

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P50

Dafna D. Gladman

P577

2016-02-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26866934

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis